You can draw your own conclusions as to why the posters who

New Post Public Reply Private Reply Replies (2) Message Board
Mo
1,155
You can draw your own conclusions as to why the posters who admit they are not IPIX shareholders continue to post on the other board on a 3 cent stock? It has been a difficult time for actual IPIX shareholders since the B-CV19 trial failed to meet endpoint goals. I personally and incorrectly believed that Brilacidin would meet endpoints in the CV19 trial based on previous success in efficacy and safety in other trials and the extensive testing at the Regional Biocontainment Lab. The sad truth is that IPIX share price would be in the dollars per share today vs 3 cents if this trial had been a success. There are endless people and organizations that some want to point fingers at for this failure including the FDA, Fauci, Leo, the Russians, CRO’s etc. Everyone has their own list and ranking of the culprits.

I personally only have 2 entities to blame.

#1 The Criminal Hedge Fund Short Selling Cabal.

IMO this NSS attack has been in place for 7 years or so. Leo’s biggest fault was not recognizing this sooner and raising cash while SP was over $2 per share. IMO if the hedge funds had not illegally targeted IPIX, Leo would have been able to raise sufficient cash without significant dilution. If capital had not been so extremely expensive due to artificial and illegal SP compression, Brilacidin would have been an approved drug long before the world had ever heard of Covid. The only glimmer of good news is that the criminals continue to have massive NSS exposure. If they had covered their naked position on IPIX, the paid multi identities would be long gone. Their plan is to never have to cover their position by putting their targeted companies out of business. To force a NSS cover, Leo would need to execute significant milestones (major license agreement, merge or buyout). IPIX investors that have hung on to some or all of their position can only hope Leo can put some type of deal together. The verbiage in the recent 10-Q indicates that IPIX science will not advance until some type of structured deal is in place. Until that time IMO Leo will continue to minimize expenses.

#2 Myself.

No one put a gun to my head to buy IPIX shares. I did my own due diligence and weighed what I felt were the risks vs the rewards and incorrectly determined that IPIX was a potentially lucrative investment. Up to this point in time I have been wrong in my assessment. Time will tell if IPIX will become a profitable investment but all prior guestimations of potential SP went out the window with the failed trial. Every SP guestimation was based on the assumption that Brilacidin would become a dominant treatment for CV19 which is highly unlikely at this point in time. That assumption has not come to fruition.

There are IPIX investors that I personally know who have completely sold their entire position and moved on, many of who have sold 20% to 50% of their position. There are also a few investors that continue to add to their positions in this 3 cent range to lower their average cost. IMO any investor who intended to sell some or all of their IPIX shares has already done so.

So what now? Those of us who have held a significant percentage of our IPIX holdings can only wait while IPIX appears to be in a holding pattern. Either Leo is successful in putting together some type of deal or structure whereas shareholders could still potentially make a profit or if not IPIX SP will continue to drift lower. I still believe in the science and I am hopeful that Leo can pull something off. As we wait do not forget who is responsible for the position IPIX is in.


14

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Corgi Re Modernizes Reinsurance with Tech-Focus

Updated Category News Views 4

Amidst the hullabaloo of the reinsurance world, Corgi Insurance is attempting something rather bold. They're flinging open the doors to innovation with a new brainchild, Corgi Re, promising to shake off the dust from an industry that still clings to the bygone era of spreadsheets and marathon underwriting cycles. The aim? Fire up modern underwriting technology and...

Continue Reading
AWOL Vision's LuxVision: Pushing Home Cinema Limits

Updated Category News Views 1

AWOL Vision Leaps into the Future at IFA 2026 You'll never look at home entertainment the same way. AWOL Vision's grand entrance at IFA 2026 in Berlin isn't just about a shiny new gadget; it's a full-blown mission to redefine what your living room can do. With its debut of the LuxVision projector, they're not just holding a torch—they're carrying a flamethrower into the...

Continue Reading
Costa Rica's Summit Draws Global Investors, Buyers

Updated Category News Views 4

Costa Rica's Big Stage for Business and Opportunity You might look at Costa Rica and think of lush rainforests and coffee beans, but right now, it's a hub bustling with suits, spreadsheets, and strategic meetings. Over three days, the Costa Rica Trade & Investment Summit (CRTIS) gathered nearly half a thousand buyers and investors all under one roof in San José. Local...

Continue Reading
Holland America Evolution: Revamping Luxury at Sea

Updated Category News Views 2

Setting Sail on a Fresh Wave of Luxury It's a whole new world aboard the Oosterdam, folks. Holland America's making waves with the debut of a reimagined Ocean Bar that promises to inject a healthy dose of glamour back into cruising. Forget the stuffy maritime tales of yesteryear; this isn't just a facelift—it's a full-blown Renaissance at sea. A nod to the golden age of...

Continue Reading
Edgewell Prepares for Key Discussion at Barclays Conference

Updated Category News Views 5

Upcoming Fireside Chat: Edgewell's Moment of Candor Alright, folks, Edgewell Personal Care Company is about to sit in a hot seat, at the Barclays 19th Annual Global Consumer Conference. You know the deal, it’s where big shots like Rod Little, the President and CEO, and Fran Weissman, the CFO, spill the beans about where the company might be headed next. Hold on to your...

Continue Reading
CGX Hits Big Stage with New Obstacle Racing Shoes

Updated Category News Views 1

A Bold Step into Obstacle Racing Today, CGX is shaking things up in the world of obstacle racing. The Chinese footwear brand launched its CGX&OCR R1010 and R1020 shoes right at the UIPM 2026 Obstacle World Championships in Beijing. Talk about a grand entrance. Targeting high-stakes international competition, these shoes are set to redefine how athletes tackle those...

Continue Reading
Zum Drivers Shine as New School Year Begins

Updated Category News Views 1

Opening the School Year with High Hopes Zum's crew of enthusiastic drivers hit the streets with a mission: kickstarting the new school year with a sense of excitement that feels fresh, even to a grizzled trader like me. These folks are doing more than just turning the ignition, they’re handling a vital cog in the education machine. From Fresno down to Rockford, you’ll...

Continue Reading
AEC Firms Revamp Strategies Amid Talent Tug-of-War

Updated Category News Views 4

The State of Compensation in AEC Sit back and chew on this—AEC firms are playing a whole new ball game when it comes to compensating their talent. FMI Corporation’s 2026 Compensation Trends Study is putting a spotlight on what really goes on behind the scenes in architecture, engineering, and construction firms. This is about more than just tossing some coin for a...

Continue Reading
Art Ave Spurs Rebirth in Downtown DC: A Template for Revival

Updated Category News Views 7

Turning Streets into Art Galleries No one would have believed a stretch of DC's bureaucratic offices was about to morph into a vibrant destination worthy of major art aficionados. But here we are, tipping our hats to the Golden Triangle Business Improvement District (BID), who just snagged the IDA Downtown Achievement Award of Excellence for their Art Ave project. Not...

Continue Reading
Dr. Anastasatos to Speak on Endoscopic Brow Lift in Crete

Updated Category News Views 3

Conference Spotlight: Endoscopic Brow Lift Plastic surgeons from across the globe are gathering in Crete, Greece, for a conference that promises to shake up the aesthetic world. Among the big names is Dr. John M. Anastasatos, who'll be lifting more than just eyebrows with his presentation on the endoscopic brow lift. This isn't just another facelift spiel—no sir—this...

Continue Reading

Top 5 Most Recently Viewed Articles

RAPT Therapeutics Set to Unveil Key Clinical Findings Soon

Updated Category News Views 292

RAPT Therapeutics Prepares for Data Release on RPT904 Trial RAPT Therapeutics, Inc. (NASDAQ: RAPT), a biopharmaceutical company dedicated to developing innovative therapies for various inflammatory and immunological diseases, is gearing up to present key topline data. The focus of this report will be on its promising Phase 2 clinical trial of RPT904, specifically aimed at...

Continue Reading
Cohen & Steers Fund Updates on Distribution Sources

Updated Category News Views 148

Cohen & Steers REIT and Preferred and Income Fund, Inc. Acknowledges Distribution Sources This notice is designed for the shareholders of Cohen & Steers REIT and Preferred and Income Fund, Inc. (NYSE: RNP) to provide them with key information about the upcoming sources of distributions. The Fund aims to inform its shareholders about the payments scheduled and the...

Continue Reading
How Emerging Markets Outperform the S&P 500 Right Now

Updated Category News Views 171

Emerging Markets Surge Ahead Emerging markets have demonstrated remarkable resilience and growth, outpacing the S&P 500 by a significant margin in recent years. The iShares Core MSCI Emerging Markets ETF (IEMG) has reported a stunning 44% year-over-year increase, effectively tripling the gains seen by the S&P 500. This performance comes as emerging markets break through...

Continue Reading
Celebrate Creativity with HitPaw's Exciting Easter Sale 2025

Updated Category News Views 112

HitPaw Unveils Exciting Easter Savings for Creators HitPaw, a renowned name in multimedia software solutions, is rolling out an impressive Easter Sale that aims to revolutionize how creators work with digital media. As the bright colors of Easter remind us of creativity and renewal, HitPaw is launching its 'Hop into Easter Savings' promotion to empower users in the...

Continue Reading
Walmart Options Trading Insights: What Investors Should Know

Updated Category News Views 64

Notable Trends in Walmart's Options Trading Walmart's recent options trading activity has caught the attention of investors. It seems that wealthy traders are adopting a bearish view on Walmart (WMT), sparking questions about the potential direction of the stock market. There’s been some unusual options activity that points to possible changes in market sentiment. Our...

Continue Reading